Article Figures & Data
Figures
- FIGURE 1.
Molecular structure of 68Ga-FAPI-2 and 68Ga-FAPI-4.
- FIGURE 2.
68Ga-FAPI-2 and 68Ga-FAPI-4 at different imaging time points (10 min, 1 h, and 3 h after injection) in 2 patients with metastasized breast cancer. Rapid tumor targeting and fast blood clearance are followed by long plateau phase without relevant change in image contrast (top). In comparison to 68Ga-FAPI-2, 68Ga-FAPI-4 is characterized by prolonged tumor retention time (bottom). LW = lumbar body.
- FIGURE 3.
Intraindividual comparison of 6 patients with 6 different tumor entities undergoing 18F-FDG PET and 68Ga-FAPI PET imaging within less than 9 d. Five of 6 patients present similar strong tumor uptake with 18F-FDG and 68Ga-FAPI, and 3 of 6 could benefit from lower background in liver or pharyngeal mucosa. In contrast, iodine-negative thyroid cancer patient presented only minor 68Ga-FAPI tracer uptake compared with 18F-FDG. Ca = cancer; NSCLC = non–small cell lung cancer.
- FIGURE 4.
PET-based biodistribution analysis of 6 patients intraindividually comparing 18F-FDG PET and 68Ga-FAPI PET, imaged at 1 h after injection. GI = gastrointestinal.
- FIGURE 5.
Interindividual comparison of 25 patients examined with 68Ga-FAPI-2 and 25 patients examined with 68Ga-FAPI-4 PET at 1 h after injection. GI = gastrointestinal.
Tables
Patient no. Sex Age MBq Diagnosis Tracer 1 F 89 312 Breast cancer 68Ga-FAPI-2 2 M 55 298 Colorectal cancer 68Ga-FAPI-2, 18F-FDG 3 M 56 256 Cancer of unknown primary 68Ga-FAPI-2 4 M 64 336 Head and neck cancer 68Ga-FAPI-2 5 M 66 196 Head and neck cancer 68Ga-FAPI-2 6 F 64 202 Head and neck cancer 68Ga-FAPI-2 7 F 65 178 Head and neck cancer 68Ga-FAPI-2 8 M 59 325 Head and neck cancer 68Ga-FAPI-2 9 M 68 255 Head and neck cancer 68Ga-FAPI-2, 18F-FDG 10 M 70 212 Hepatocellular carcinoma 68Ga-FAPI-2 11 M 66 308 Liposarcoma 68Ga-FAPI-2 12 M 78 222 Non–small cell lung cancer 68Ga-FAPI-2, 18F-FDG 13 F 66 268 Non–small cell lung cancer 68Ga-FAPI-2 14 F 58 126 Esophagus cancer 68Ga-FAPI-2, 18F-FDG 15 M 70 134 Esophagus cancer 68Ga-FAPI-2 16 M 31 307 Pancreatic cancer 68Ga-FAPI-2, 18F-FDG 17 M 52 167 Pancreatic cancer 68Ga-FAPI-2 18 M 56 222 Pancreatic cancer 68Ga-FAPI-2 19 F 73 142 Pancreatic cancer 68Ga-FAPI-2 20 M 74 122 Prostate cancer 68Ga-FAPI-2 21 M 77 318 Prostate cancer 68Ga-FAPI-2 22 M 60 285 Renal cell carcinoma 68Ga-FAPI-2 23 M 77 225 Thyroid cancer 68Ga-FAPI-2, 18F-FDG 24 M 55 270 Thyroid cancer 68Ga-FAPI-2 25 F 60 238 Uterus cancer 68Ga-FAPI-2 26 F 57 263 Breast cancer 68Ga-FAPI-4 27 F 44 220 Colorectal cancer 68Ga-FAPI-4 28 M 66 286 Colorectal cancer 68Ga-FAPI-4 29 M 55 244 Colorectal cancer 68Ga-FAPI-4 30 M 46 247 Cancer of unknown primary 68Ga-FAPI-4 31 F 82 236 Head and neck cancer 68Ga-FAPI-4 32 M 51 263 Head and neck cancer 68Ga-FAPI-4 33 M 84 246 Hepatocellular carcinoma 68Ga-FAPI-4 34 M 77 299 Non–small cell lung cancer 68Ga-FAPI-4 35 F 58 217 Non–small cell lung cancer 68Ga-FAPI-4 36 M 64 255 Non–small cell lung cancer 68Ga-FAPI-4 37 F 56 250 Ovarian cancer 68Ga-FAPI-4 38 F 67 260 Pancreatic cancer 68Ga-FAPI-4 39 F 76 243 Pancreatic cancer 68Ga-FAPI-4 40 F 55 293 Pancreatic cancer 68Ga-FAPI-4 41 M 52 239 Pancreatic cancer 68Ga-FAPI-4 42 M 61 198 Pancreatic cancer 68Ga-FAPI-4 43 M 73 277 Pancreatic cancer 68Ga-FAPI-4 44 M 57 275 Pancreatic cancer 68Ga-FAPI-4 45 M 60 237 Pancreatic cancer 68Ga-FAPI-4 46 M 31 233 Pancreatic cancer 68Ga-FAPI-4 47 M 71 249 Prostate cancer 68Ga-FAPI-4 48 M 64 227 Prostate cancer 68Ga-FAPI-4 49 M 72 276 Thyroid cancer 68Ga-FAPI-4 50 F 27 204 Thyroid cancer 68Ga-FAPI-4 Site 68Ga-FAPI-2 68Ga-FAPI-4 Adrenals 1.23E−02 1.12E−02 Brain 9.54E−03 9.11E−03 Breasts 9.58E−03 8.88E−03 Gallbladder wall 1.19E−02 1.13E−02 Lower large intestine wall 1.23E−02 1.17E−02 Small intestine 1.19E−02 1.13E−02 Stomach wall 1.13E−02 1.06E−02 Upper large intestine wall 1.17E−02 1.11E−02 Heart wall 4.73E−02 2.02E−02 Kidneys 4.45E−02 4.43E−02 Liver 1.51E−02 1.46E−02 Lungs 1.09E−02 9.89E−03 Muscle 1.04E−02 9.91E−03 Ovaries 1.24E−02 1.19E−02 Pancreas 1.23E−02 1.13E−02 Red marrow 3.28E−02 2.08E−02 Osteogenic cells 2.94E−02 2.16E−02 Skin 9.01E−03 8.63E−03 Spleen 2.62E−02 1.05E−02 Testes 1.04E−02 1.01E−02 Thymus 1.15E−02 1.01E−02 Thyroid 1.03E−02 9.82E−03 Urinary bladder wall 8.89E−02 9.91E−02 Uterus 1.33E−02 1.30E−02 Total body 1.19E−02 1.09E−02 Effective dose (mSv/MBq) 1.80E−02 1.64E−02
Jump to section
Related Articles
Cited By...
- Mars Shot for Nuclear Medicine, Molecular Imaging, and Molecularly Targeted Radiopharmaceutical Therapy
- Targeting Fibroblast Activation Protein: Radiosynthesis and Preclinical Evaluation of an 18F-Labeled FAP Inhibitor
- Disentangling inflammatory from fibrotic disease activity by fibroblast activation protein imaging
- Design and Development of 99mTc-Labeled FAPI Tracers for SPECT Imaging and 188Re Therapy
- The Role of 68Ga-FAPI PET/CT for Patients with Malignancies of the Lower Gastrointestinal Tract: First Clinical Experience
- The Future of Nuclear Medicine Depends on the Quality of Its Research: Researchers at the University of Heidelberg Receive the Award for Best Article of the Year
- Radiation Dosimetry and Biodistribution of 68Ga-FAPI-46 PET Imaging in Cancer Patients
- Reversibility of 68Ga-FAPI-2 Trapping Might Prove an Asset for PET Quantitative Imaging
- Theranostics Targeting Fibroblast Activation Protein in the Tumor Stroma: 64Cu- and 225Ac-Labeled FAPI-04 in Pancreatic Cancer Xenograft Mouse Models
- FAP: The Next Billion Dollar Nuclear Theranostics Target?
- A Conversation Between Uwe Haberkorn and Johannes Czernin
- Development of Fibroblast Activation Protein-Targeted Radiotracers with Improved Tumor Retention
- Future of Theranostics: An Outlook on Precision Oncology in Nuclear Medicine
- The Future of Nuclear Medicine as an Independent Specialty
- Photoacoustic imaging as a tool to probe the tumour microenvironment
- 68Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer